{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-012523","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2022-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.484000+00:00","generated_at":"2026-06-24T19:13:17.070829+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"KalVista FY2022 net loss $82.3M (-$3.36/share); cash $166.2M; sebetralstat Phase 3 on track","bullets":["Net loss $82.3M ($3.36 loss per share) vs $46.2M ($2.42) prior year; R&D spend $70.2M.","Cash & marketable securities $166.2M at April 30, 2022, down from $248.9M; funding into early 2024.","Sebetralstat Phase 3 KONFIDENT trial enrollment on track; data expected H2 2023. EU orphan designation received.","KVD824 Phase 2 KOMPLETE trial for HAE prevention on track; data expected mid-2023.","Appointed Patrick A. Treanor (COO of Pathalys Pharma) to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-012523","json":"https://secwatch.observer/filing/0000950170-22-012523.json","markdown":"https://secwatch.observer/filing/0000950170-22-012523.md","text":"https://secwatch.observer/filing/0000950170-22-012523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017022012523/0000950170-22-012523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017022012523/kalv-20220707.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T19:13:17.070829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}